Ερευνητική δραστηριότητα- ΓΝΑ Ιπποκράτειο Ομιλητής: Nικόλαος Ιωακειμίδης Επιστημονικός Συνεργάτης Α Πανεπιστημιακής Καρδιολογικής Κλινικής, Μονάδα Περιφερικών Αγγείων, ΓΝΑ Ιπποκράτειο Υπεύθυνοι Μονάδας Περιφερικών Αγγείων: Αναπλ. Καθηγητής Χ. Βλαχόπουλος Καθηγητής Δ. Τούσουλης 1
Δεν έχω καμία σύγκρουση συμφερόντων
Ερευνητική Ομάδα Χ. Βλαχόπουλος Κ. Αζναουρίδης Ν. Ιωακειμίδης Δ. Τερεντές-Πρίντζιος Χ. Γεωργακόπουλος Ι. Κουτάγιαρ Α. Ρηγάτου Ν. Σκληρός Ν. Μάγγας Ι. Γουργούλη Μ. Αμπντελρασούλ Π. Ξαπλαντέρης Μονάδα Σεξουαλικής Υγείας Κ. Ρόκκας Ζ. Κρατήρας 3
Ερευνητική-Επιστημονική Δραστηριότητα Δημοσιεύσεις Συνέδρια
Δημοσιεύσεις 2016 Δημοσιεύσεις Δημοσιεύσεις (n=25) Συγχρονικές Μελέτες 4% 8% 13% Προοπτικές μελέτες 8% Μελέτες Επιβίωσης 17% 4% Ανασκοπήσεις Τυχαιοποιημένες μελέτες Γράμματα-Συντακτικά κείμενα 17% 21% Κατευθυντήριες οδηγίες- Ομοφωνίες Μετα-αναλύσεις 8% Πολυκεντρικές μελέτες
Δημοσιεύσεις 2016 Κατευθυντήριες οδηγίες Directions are instructions given to explain how. Direction is a vision offered to explain why. Simon Sinek 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL; Authors/Task Force Members.; Additional Contributor.. Eur Heart J. 2016 Oct 14;37(39):2999-3058
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL; Authors/Task Force Members.; Additional Contributor.. Eur Heart J. 2016 Oct 14;37(39):2999-3058 Δημοσιεύσεις 2016 Κατευθυντήριες οδηγίες
Δημοσιεύσεις 2016 Consensus Statements Validation of non-invasive central blood pressure devices: ARTERY Society task force consensus statement on protocol standardization. Sharman JE, Avolio AP, Baulmann J, Benetos A, Blacher J, Blizzard CL, Boutouyrie P, Chen CH, Chowienczyk P, Cockcroft JR, Cruickshank JK, Ferreira I, Ghiadoni L, Hughes A, Jankowski P, Laurent S, McDonnell BJ, McEniery C, Millasseau SC, Papaioannou TG, Parati G, Park JB, Protogerou AD, Roman MJ, Schillaci G, Segers P, Stergiou GS, Tomiyama H, Townsend RR, Van Bortel LM, Wang J, Wassertheurer S, Weber T, Wilkinson IB, Vlachopoulos C. Eur Heart J. 2017 Methodology and technology for peripheral and central blood pressure and blood pressure variability measurement: current status and future directions - Position statement of the European Society of Hypertension Working Group on blood pressure monitoring and cardiovascular variability. Stergiou GS, Parati G, Vlachopoulos C, Achimastos A, Andreadis E, Asmar R, Avolio A, Benetos A, Bilo G, Boubouchairopoulou N, Boutouyrie P, Castiglioni P, de la Sierra A, Dolan E, Head G, Imai Y, Kario K, Kollias A, Kotsis V, Manios E, McManus R, Mengden T, Mihailidou A, Myers M, Niiranen T, Ochoa JE, Ohkubo T, Omboni S, Padfield P, Palatini P, Papaioannou T, Protogerou A, Redon J, Verdecchia P, Wang J, Zanchetti A, Mancia G, O'Brien E. J Hypertens. 2016
Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis. PCSK9 levels are modestly but significantly associated with increased risk of total CV events. These results suggest a predictive role of PCSK9 levels on CV health and support the possible clinical role of PCSK9 inhibitors Vlachopoulos C, Terentes-Printzios D, Georgiopoulos G, Skoumas I, Koutagiar I, Ioakeimidis N, Stefanadis C, Tousoulis D. Atherosclerosis. 2016 Sep;252:50-60.
Δημοσιεύσεις 2016 Συγχρονικές-Προοπτικές μελέτες παρατήρησης Vlachopoulos C, Ioakeimidis, et al. Am J Hypertension 2016 Ioakeimidis N, Vlachopoulos C et al. J Hypertens 2016 Αυξημένες τιμές του δείκτη ενίσχυσης των ανακλώμενων κυμάτων και των πιέσεων στην ανιούσα αορτή σχετίζονται με αυξημένο κίνδυνο καρδιαγγειακών συμβάντων σε άνδρες με στυτική δυσλειτουργία Η μειωμένη συστολική ροή στις αρτηρίες του πέους συσχετίζεται με αυξημένο κίνδυνο για μείζονα καρδιαγγειακά συμβάματα στους υπερτασικούς ασθενείς Inverse association of total testosterone with central haemodynamics and left ventricular mass in hypertensive men. Vlachopoulos C, Pietri P, Ioakeimidis N, Aggelis A, Terentes-Printzios D, Abdelrasoul M, Gourgouli I, Stefanadis C, Tousoulis D. Atherosclerosis. 2016
Δημοσιεύσεις 2016 Γράμματα-Συντακτικές επιστολές Pulse Pressure and Cardiovascular Death. Aznaouridis K, Vlachopoulos C, Tousoulis D. J Am Coll Cardiol. 2016 Jul 5;68(1):131-2. doi: 10.1016/j.jacc.2016.03.586. No abstract available. Angiotensin converting enzyme inhibitors and walking distance: Have we walked the whole distance? Vlachopoulos C, Terentes-Printzios D, Aboyans V, Brodmann M, De Carlo M, Tousoulis D. Atherosclerosis. 2016 Sep;252:199-200. Vlachopoulos C et al. JACC 2016
ΑΗΑ, ACC, ESC, ESH, Αrtery, ESSM : 34 abstracts (9 oral presentations) Συνέδρια 2015-2016
Συνέδρια 2015-2016 Arterial compliance is associated with target organ damage in hypertensives D. Terentes-Printzios 1, C. Vlachopoulos 2, G. Vyssoulis 1, P. Pietri 1, P. Xaplanteris 1, M. Abdelrasoul 1, E. Paschalidis 1, A. Rigatou 1, N. Ioakeimidis 1, D. Tousoulis 1 Background/Introduction: Total arterial compliance (TAC) has been recognized as an independent risk factor for cardiovascular events. Hypertension is associated with higher cardiovascular risk as well as several markers of subclinical target organ damage (TOD). Purpose: We sought to investigate relationship between TAC and markers of TOD in never-treated hypertensives. Methods: We enrolled 990 consecutive essential hypertensives (mean age 53±12 years, 526 males) without known cardiovascular disease (CVD). Markers of subclinical TOD [ankle-brachial index (ABI), estimated glomerular filtration rate (egfr), left ventricular mass index (LVMI) and pulse wave velocity (PWV),] were evaluated in all patients. ABI was calculated by dividing the highest ankle systolic blood pressure by the highest brachial systolic blood pressure. LVMI was assessed echocardiographically using the Devereux formula. Carotid-femoral PWV was estimated with the Complior device. egfr was calculated by the Cockcroft-Gault formula. Augmentation index (AIx@75) was also assessed as an index of wave reflections. The ratio of stroke volume to pulse pressure was measured echocardiographically as a surrogate of TAC. Results: In multivariable regression analysis, TAC exhibited significant association with LVMI (p=0.004, adjusted R2 of model=0.318), PWV (p<0.001, adjusted R2 of model=0.335) ABI (p<0.001, adjusted R2 of model=0.334) but not with egfr and AIx@75. In further analysis, TAC was associated with TOD as suggested by the 2013 European Guidelines for Hypertension [left ventricular hypertrophy (LVMI>115 g/m2 in men and >95 g/m2 in women), increased PWV (PWV>10m/s), decreased ABI (ABI<0.9) and decreased renal function (egfr<60ml/min)]. Specifically, TAC exhibited significant association with left ventricular hypertrophy (p=0.003, adjusted R2 of model=0.318), increased aortic stiffness (p<0.001, adjusted R2 of model=0.325), decreased ABI (p=0.001, adjusted R2 of model=0.320) and renal dysfunction (p=0.003, adjusted R2 of model=0.318). These associations were independent of age, gender, mean blood pressure, body-mass index, smoking habits, glucose, low-density lipoprotein and C-reactive protein. Conclusions: Our findings support the close relationship between TAC and TOD in hypertension, as well as, the predictive ability of TAC for TOD Best Poster Presentation ESC 2016
Best HP presentation Male Sexual Function European Society for Sexual Medicine 2017
Ευχαριστώ πολύ!